Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.